Skip to main content

Novo Nordisk vs Pfizer: Revenue, Profit and Business Model

Novo Nordisk had ~$47B of annual revenue in FY2025 and ~$15.6B of net income. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.

Latest financial snapshot

Novo Nordisk

Latest annual revenue
~$47B (FY2025)
Net income
~$15.6B
Net margin
33.1%
Revenue growth
+16.8% a year, FY2019–FY2025

Pfizer

Latest annual revenue
$62.6B (FY2025)
Net income
$7.8B
Net margin
12.4%
Revenue growth
+1.9% a year, FY2016–FY2025

Financial summary

Novo Nordisk

Sales grew from ~$18.5B (DKK 122.0B) in 2019 to ~$47B (DKK 309.1B) in 2025, and net profit rose from ~$5.93B (DKK 39.0B) to ~$15.6B (DKK 102.4B), driven by Ozempic and Wegovy. Growth slowed to 6.4% in reported DKK in 2025 as US prices fell and competition rose. In H1 2026 reported sales were ~$26.6B (DKK 175.3B), inflated by a one-off 340B rebate provision reversal; adjusted sales were ~$22.6B (DKK 148.6B). Q2 2026 adjusted sales rose 7% at constant exchange rates, and management guided full-year 2026 adjusted sales and operating profit growth of 0% to -6% at CER.

Pfizer

Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Revenue and profit by year

Novo Nordisk

Novo Nordisk revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$47B~$15.6B33.1%+6.4%Source
FY2024~$44.1B~$15.4B34.8%+25.0%Source
FY2023~$35.3B~$12.7B36.0%+31.3%Source
FY2022~$26.9B~$8.4B31.4%+25.7%Source
FY2021~$21.4B~$7.3B33.9%+10.9%Source
FY2020~$19.3B~$6.4B33.2%+4.0%Source
FY2019~$18.5B~$5.9B31.9%—Source
Full Novo Nordisk financials

Pfizer

Pfizer revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$62.6B$7.8B12.4%-1.6%Source
FY2024$63.6B$8B12.6%+6.8%Source
FY2023$59.6B$2.1B3.6%-41.1%Source
FY2022$101.2B$31.4B31.0%+24.5%Source
FY2021$81.3B$22B27.0%+95.2%Source
FY2020$41.7B$9.2B22.0%+1.8%Source
FY2019$40.9B$16B39.2%+0.2%Source
FY2018$40.8B$11.2B27.3%-22.3%Source
FY2017$52.5B$21.3B40.6%-0.5%Source
FY2016$52.8B$7.2B13.7%—Source
Full Pfizer financials

Where the revenue comes from

Novo Nordisk

  • GLP-1 Diabetes MedicinesMajor

    Ozempic, Rybelsus, and related diabetes products sold globally.

  • Obesity Care

    Major growth

    Wegovy and related obesity-care products sold through prescription channels.

  • Insulin And Diabetes CareMaterial

    Insulin and other diabetes medicines across developed and emerging markets.

  • Rare Disease

    Complementary

    Hemophilia, growth hormone, and rare endocrine therapies.

  • Pipeline And Lifecycle ExpansionFuture

    New indications, formulations, and next-generation metabolic medicines.

Pfizer

  • Patented medicines

    Core revenue

    Prescription drugs protected by exclusivity and clinical differentiation.

  • Vaccines

    Major revenue contributor

    Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.

  • Oncology

    Strategic growth driver

    Cancer medicines, antibody-drug conjugates, and Seagen-related assets.

  • Hospital and anti-infective products

    Meaningful contributor

    Sterile injectables, anti-infectives, and hospital therapies.

  • Collaborations and alliances

    Supplemental

    Co-promoted products and partnered scientific platforms.

Business model and strategy

Novo Nordisk

How it makes money

Novo Nordisk A/S is a world-leading Danish healthcare company that develops, manufactures, and markets biological medicines focused primarily on diabetes care and obesity management, supplemented by rare disease therapies.

Growth strategy

Under CEO Mike Doustdar the strategy is to cut costs (about 9,000 roles targeted in 2025, with reported headcount down further since), push volume through cheaper self-pay and oral options such as the Wegovy pill, roll out Wegovy 7.2 mg internationally, and rebuild the pipeline through deals such as the Akero Therapeutics acquisition for MASH and in-licensing agreements.

Competitive advantage

Novo Nordisk commands an unmatched century-long moat in protein engineering, industrial-scale yeast fermentation, and specialized pen-injector drug delivery systems. Controlling approximately one-third of the global diabetes treatment market, Novo Nordisk possesses unrivaled clinical relationships with endocrinologists, primary care physicians, and healthcare payers worldwide.

Novo Nordisk business model in full

Pfizer

How it makes money

Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.

Growth strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).

Competitive advantage

Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.

Pfizer business model in full

Questions about Novo Nordisk vs Pfizer

Which company has higher revenue — Novo Nordisk A/S or Pfizer Inc.?

Novo Nordisk A/S had ~$47B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Pfizer Inc. is the larger business, with Novo Nordisk A/S showing a smaller revenue base.

What is the market cap of Novo Nordisk A/S vs Pfizer Inc.?

Novo Nordisk A/S's market capitalisation stands at $170.0B, while Pfizer Inc.'s is $160.3B. Novo Nordisk A/S carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Pfizer Inc..

How does revenue per employee compare for Novo Nordisk A/S and Pfizer Inc.?

Novo Nordisk A/S has $704k / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Novo Nordisk A/S and Pfizer Inc. make money?

Novo Nordisk A/S and Pfizer Inc. generate revenue in fundamentally different ways. Novo Nordisk A/S: Novo Nordisk A/S is a world-leading Danish healthcare company that develops, manufactures, and markets biological medicines focused primarily on diabetes care and obesity management, supplemented by rare disease therapies. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which company is valued higher relative to revenue — Novo Nordisk A/S or Pfizer Inc.?

On a price-to-sales (P/S) basis, Novo Nordisk A/S trades at 3.6x P/S and Pfizer Inc. at 2.6x P/S. Novo Nordisk A/S commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Novo Nordisk A/S bigger than Pfizer Inc.?

By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to Novo Nordisk A/S (~$47B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Novo Nordisk vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.